[The clinical practice guidelines for primary hyperparathyroidism, short version]

Area of Science:

• Endocrinology
• Internal Medicine

Background:

• Primary hyperparathyroidism (PHPT) is an endocrine disorder marked by excessive parathyroid hormone (PTH) secretion, leading to elevated blood calcium.
• Symptomatic PHPT negatively impacts quality of life, causes disability, and increases mortality risk due to hypercalcemia and PTH's catabolic effects.
• PHPT incidence has risen, particularly mild forms, driven by routine calcium screening; its prevalence and diverse manifestations engage multiple medical specialties.

Purpose of the Study:

• To present the key aspects of the 2020 Russian guidelines for primary hyperparathyroidism management.
• To consolidate diagnostic, therapeutic, and follow-up recommendations for PHPT.
• To address specific patient populations, including those with hereditary forms, parathyroid carcinoma, and pregnancy-associated PHPT.

Main Methods:

• Review of the 2020 Russian guidelines for PHPT.
• Inclusion of laboratory and instrumental diagnostic methods.
• Discussion of differential diagnosis, surgical and conservative treatment options, and follow-up protocols.

Main Results:

• The guidelines provide a comprehensive framework for PHPT management.
• Recommendations cover diagnosis, treatment strategies, and long-term patient monitoring.
• Specific guidance is offered for hereditary PHPT, parathyroid carcinoma, and PHPT in pregnancy.

Conclusions:

• The 2020 Russian guidelines offer a standardized approach to PHPT care.
• Adherence to these guidelines can improve patient outcomes and quality of life.
• The guidelines emphasize a multidisciplinary approach for managing diverse PHPT presentations.